← brief for 2026-09-11 · Slowing decline

Cardiorenal Protection in Type 2 Diabetes: A Systematic Review Comparing Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors.

Article A Peer reviewed Meta-analysis or large trial

Key takeaways

This systematic review looked at many large trials and found both GLP-1 receptor agonists and SGLT2 inhibitors slow kidney decline and lower heart risks in type 2 diabetes, even beyond lowering blood sugar. The benefit was clear across hundreds of patients and hard outcomes like kidney failure or death.

Who did this work

Branigan P · Duong VNY · Branigan S

Source

Article · PubMed, the drug frontier · 2026 Sep 10
https://pubmed.ncbi.nlm.nih.gov/42724505/